
The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

